The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Catalent Inc. (CTLT) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $47.96. The Catalent Inc. has recorded 25,723 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader.
The company is listed on the NYSE and operates within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $47.96 and fluctuated between $48.95 as its day high and $47.54 as its day low. The current market capitalization of Catalent Inc. is $8.68B. A total of 2.27 million shares were traded on the day, compared to an average of 3.25M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, CTLT has seen 12 BUY and 3 SELL insider trades, representing the acquisition of 49,788 and the disposition of 3,652 shares. Over the last 12 months, there were 47 BUYs and 46 SELLs from insiders. Insiders purchased 315,487 shares during that period but sold 592,774.
In the most recent transaction, Boerman Manja sold 780 shares of CTLT for 51.70 per share on Dec 05. After the transaction, the Pres. BioModalities Division now owns 15,860 company shares. In a previous transaction on Oct 31, Grippo Michael J sold 2,451 shares at 65.83 per share. CTLT shares that SVP, Strategy & Corp. Dev. owns now total 17,792.
Among the insiders who sold shares, Hawkeswood Thomas W disposed of 930 shares on Oct 10 at a per-share price of $77.46. This resulted in the Pres. Pharma Prod Delivery Div holding 5,364 shares of CTLT after the transaction. In another insider transaction, Hopson Ricky sold 2,216 shares at $89.59 per share on Aug 31. Company shares held by the Pres. Clinical Dev Supply Div now total 17,095.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for CTLT in the last 3 months, the mean price target is $70.82 with high estimates of $100.00 and low estimates of $44.00. In terms of 52-week highs and lows, CTLT has a high of $115.33 and a low of $40.69.
As of this writing, CTLT has an earnings estimate of $0.56 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of $0.66 per share and a lower estimate of $0.48. The company reported an EPS of $1.04 in the last quarter, which was 10.60% higher than expectations of $0.94.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 16 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CTLT is Underweight with a score of 4.09. A total of 8 analysts rated the stock as Buy while 3 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.